Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Lilly Signs Up With Cancer Institutes
by Michael McCoy
June 22, 2015
| A version of this story appeared in
Volume 93, Issue 25
Eli Lilly & Co. has formed drug development partnerships with two cancer-oriented institutes. Lilly and Dana-Farber Cancer Institute have a three-year deal under which Dana-Farber will provide R&D expertise for a number of early-stage Lilly oncology compounds. With Sarah Cannon Research Institute, Lilly will codevelop LY3023414, a PI3K/mTOR dual inhibitor that is in Phase I clinical trials. SCRI, part of Hospital Corporation of America, will provide clinical development and program design for a Phase II trial.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter